Member Info for caitlin1

Come on 14.22,you know you want to.

Just keep some in here and collect your divis.Either reinvest back in Gsk or elsewhere.Try not and trade much.Just try and find quality stocks.

Getting closer to my buy price 14.22.Im happy with my divs here.

In combination, the drugs cost just under £1,500 for an 11-day course – and because Tyverb is nearing the end of its patent the cost is expected to plummet. Hope they can reduce the price so more people can use it

Come on Gsk get above 14 .you know you want to

Nice rise

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced publication of results from the 'LABA' (long acting beta2-agonist) safety study, AUSTRI (SAS115359) in the New England Journal of Medicine (NEJM). The study, which reported results in October, compared Advair® Diskus®, a combination of the LABA, salmeterol, and inhaled corticosteroid (ICS), fluticasone propionate (FP), to FP monotherapy, to assess the safety profiles of each medicine when used to treat adolescent and adult patients with asthma. This was assessed by the composite endpoint of serious asthma-related events (deaths, intubations or hospitalisations) and showed that Advair had a safety profile comparable to FP, including no asthma-related deaths in either arm. These results are being simultaneously presented at the American Academy of Asthma, Allergy and Immunology (AAAAI) Congress in Los Angeles, California. AUSTRI was undertaken as a post-marketing requirement of GSK for the US Food and Drug Administration (FDA). Three other manufacturers of LABA-containing products, which are also indicated for the treatment of asthma, are undertaking identical studies designed to evaluate whether the addition of a LABA to an ICS increased the risk of an event in the composite endpoint of serious asthma-related events in adolescents and adults with asthma. AUSTRI is the first of the large-scale safety studies to report results and was conducted in over 11,000 patients. Kate Knobil, Chief Medical Officer - Pharmaceuticals at GSK said: "We are pleased that this study, which demonstrates the safety profile of Advair, has now been presented in a well-respected, peer-reviewed journal and also presented at scientific congress. This will give physicians the opportunity to independently review the results of this study." In addition to the AUSTRI study, GSK is also conducting a second LABA safety study, VESTRI, in children with asthma aged 4 - 11 years of age. This study is on track to report at the end of Q1 2016.

1. New product growth is ahead of schedule "And as you see, we're now 682 million pounds [$957 million] in the last quarter [concerning new product growth]. We're 2 billion pounds [$2.81 billion] delivered for the full year. Obviously, if you annualize the Q4 rate, we're very -- we're running up now an annualized rate of close to 3 billion pounds [$4.21 billion], and that's why we feel confident that we're going to be able to bring forward the time at which we hit our target that we laid out in May of 6 billion pounds [$8.42 billion]. So rather than hitting that number in 2020, we think we now could hit that number up to 2 years earlier, maybe as early as 2018." One of GlaxoSmithKline's biggest issues has been its declining top line, which is a direct result of the expiration of the patent for its inhaled COPD and asthma therapy, Advair, which may face generic competition as early as 2017, and the loss of exclusivity on Lovaza. Advair, which was once a drug capable of generating $8 billion in annual sales, continues to find its pricing power pressured, and generics are eating Lovaza's revenue stream for lunch. Triumeq IMAGE SOURCE: GLAXOSMITHKLINE. What Witty wants you to understand is that the new products the company has introduced are tracking well ahead of expectations in terms of total sales. New products, which GSK classifies as 11 therapies (including a small handful that haven't been approved yet, such as shingles vaccine Shingrix), are already on pace for $4 billion in extrapolated annual sales. According to its updated projections, this group of therapies could generate $8.4 billion in annual sales by 2018 -- more than 100% expected growth in the coming three years. GSK's established product growth may be disappointing, but its up-and-coming products are certainly worth paying close attention to.

5. Our pipeline is deep and maturing "[Y]ou've got to remember, we have 93 projects listed on our pipeline chart in the results we've issued today. 71% of them are new molecular entities. 63% of those 93 projects are in Phase II or Phase III." G IMAGE SOURCE: NOVARTIS. Lastly, investors should keep in mind that GSK isn't under any pressure to cut deals any longer. GSK completely reorganized its business last year by sending its oncology business to Novartis for $16 billion, acquiring Novartis' vaccine business (minus influenza) for about $7 billion, and forging a joint venture with in consumer healthcare products. These moves gave GSK a healthy cash infusion that it can use to run its 93 clinical "projects" in the works. Based on Witty's commentary, around two-thirds of GSK's clinical studies are currently in the mid-to-late stages, which is where safety and efficacy are really illustrated, and where peak sales potential can first be estimated. With its revenue generation more geographically and operationally balanced than it was before, the company can now focus on one of the industry's deepest pipelines. The ongoing loss of revenue from Advair is likely to weigh on GSK in the near term, but the light at the end of the tunnel can finally be seen. Investors searching for a Big Pharma turnaround candidate with a healthy dividend may want to consider giving GSK a closer look.

Significant new product sales growth expected. Consistent dividend track with a yield approaching 6%. Most risks are offset by GSK’s diversification. Further growth expected from 2016/2017 pipeline. Fairly valued versus its competitors. GlaxoSmithKline (NYSE:GSK) is one of the world's leading pharmaceutical companies, with a market cap in excess of $94 billion. Throughout 2015 GSK performed strongly whilst expanding its strengths into a variety of areas, particularly new product performance. There is no doubt GSK has been affected by the current macro environment, however, it possesses the potential to recover greatly throughout 2016.

Summary GlaxoSmithKline is a health care behemoth based in the UK. It has a huge portfolio of pharmaceutical and personal care products. It is a bargain at present on the market. Seeking alpha

Summary GlaxoSmithKline is a health care behemoth based in the UK. It has a huge portfolio of pharmaceutical and personal care products. It is a bargain at present on the market. Seeking alpha

GlaxoSmithKline, which accounts for 7pc of the Woodford Equity Income fund, was “overdistributing” profits and should cut, Mr Woodford said. “I have actually told Glaxo to cut their dividend,” he said, adding that he was happy to be cast in the role of an "activist" investor in the company. "I have said to the chairman that shareholders will have their heads on spikes if they cut the dividend but don’t change strategy." Mr Woodford has been leading calls for Glaxo to split into several smaller businesses, allowing it to be run more profitably. A turnaround plan put forward by chief executive Sir Andrew Witty “won’t work”, Mr Woodford said. GlaxoSmithKline was contacted but had not responded by the time of writing. Mr Woodford said the dividend from another high-paying pharmaceutical company, AstraZeneca, was safe, however. “We have no worries over Astra,” he said.

No move day

Down we go again.

Some people paid 1.30 a share for this a few years back

Can't have blue every day.Never mind ex div soon.

Nice little rise today.

Getting close to my break even price.A bridge to far or the great escape????

Bought a few here to add to my oil portfolio.360 million barrels plus and money in the bank.Hold and wait.